Alglucosidase alfa
Alglucosidase alfa, sold under the brand name Myozyme among others, is an enzyme replacement therapy (ERT) orphan drug for treatment of Pompe disease (Glycogen storage disease type II), a rare lysosomal storage disorder (LSD).[3] Chemically speaking, the drug is an analog of the enzyme that is deficient in patients affected by Pompe disease, alpha-glucosidase. It is the first drug available to treat this disease.[1]
Clinical data | |
---|---|
Trade names | Myozyme, Lumizyme, others |
AHFS/Drugs.com | Monograph |
License data | |
Routes of administration | Intravenous[1] |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C4758H7262N1274O1369S35[2] |
Molar mass | 105338 g·mol−1[2] |
![]() ![]() |
Medical uses
Alglucosidase alfa is used as ERT treatment for children.[1]
In 2014 the U.S. Food and Drug Administration announced the approval of alglucosidase alfa for treatment of people with infantile-onset Pompe disease, including people who are less than 8 years of age. In addition, the Risk Evaluation and Mitigation Strategy (REMS) is being eliminated.[4]
Side effects
Common observed adverse reactions to alglucosidase alfa treatment are pneumonia, respiratory complications, infections and fever. More serious reactions reported include heart and lung failure and allergic shock. Myozyme boxes carry warnings regarding the possibility of life-threatening allergic response.[1]
Cost
Some health plans have refused to subsidize Myozyme for adults because it lacks approval for treatment in adults, as well as its high cost (US$300,000 per year for life).[5]
In 2015, Lumizyme was ranked the costliest drug per patient, with an average charge of $630,159.[6]
References
- "FDA Approves First Treatment for Pompe Disease" (Press release). FDA. 2006-04-28. Retrieved 2008-07-07.
- American Medical Association (USAN). "Alglucosidase alfa" (Microsoft Word). Statement on a Nonproprietary Name Adopted by the USAN Council. Retrieved 18 December 2007.
- Kishnani PS, Corzo D, Nicolino M, et al. (2007). "Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease". Neurology. 68 (2): 99–109. doi:10.1212/01.wnl.0000251268.41188.04. PMID 17151339.
- cite press release |title=FDA expands approval of drug to treat Pompe disease to patients of all ages; removes risk mitigation strategy requirements |publisher=FDA |date=2014-08-14 |url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm407563.htm
- Geeta Anand (2007-09-18). "As Costs Rise, New Medicines Face Pushback". Wall Street Journal. Dow Jones & Company. Retrieved 2008-07-07.
- https://www1.magellanrx.com/media/604882/2016mrxtrendreport_final.pdf